What Happens to Astronauts Is Happening to You

I just spent three days in a room with the people responsible for keeping human beings alive in space. Not alive in some theoretical, simulation-room way. Alive and functional — strong enough to work, sharp enough to decide, resilient enough to come home. These are the researchers, flight surgeons, engineers, and performance scientists who have to answer a question nobody in history has had to answer before: what does it actually take to send a human to Mars and get them back?

What I found was not what I expected. I expected cutting-edge certainty. What I got was a room full of extraordinarily intelligent people sitting with the uncomfortable weight of what they don't know yet — gaps in data that have been open for twenty-five years, risks that didn't show up until 2019, and a timeline that is now compressing faster than the science can keep up. This is the forefront of all medicine for humanity. Not a TED talk about it. The actual frontier. And the research happening in that room is not being talked about — which means almost nobody outside of NASA knows that the most important discoveries about human resilience, performance, and longevity are being made right now, in the context of space, and that they apply directly to your life and your body.

That changes with this newsletter. Consider this your access pass.

Here is what NASA knows for certain after sixty years of human spaceflight:

When you put a human into an extreme environment — microgravity, isolation, resource constraint, high operational demand — the body begins to adapt. Fast. Within weeks, muscle mass drops approximately 20%. Aerobic capacity falls around 15%. Bone remodels in ways that even the world's best researchers don't fully understand yet. Neuro-vestibular function shifts. Fluid moves. The spine changes shape.

And then — if the person was built right before they went in — they come back within 30 days.

That number stopped me. Thirty days to return to baseline from one of the most physiologically hostile environments a human can experience. That is not a recovery story. That is a resilience story — and it only works for the people who filled their bucket before the mission began.

This is the astronaut mirror. Hold it up and what do you see? Your body operates by the same rules. The stress of an extreme week, a brutal travel schedule, a high-stakes project, a health crisis, a season of grief — these are your missions. The question is whether you went in prepared. Whether you built the adaptive capacity before the environment demanded it. Whether your resilience bucket had anything in it when things went sideways.

But here is what made me lean forward in my seat: the biggest unsolved problem in astronaut performance science — after twenty-five years of data — is variability. Some crew members bounce back in a week. Others take much longer. Some barely lose anything. Others lose significantly more than the average. And the researchers cannot predict which person is which. They cannot correlate the exercise performed in space with the outcome on the ground. They cannot identify the upstream variable that separates the resilient from the fragile before the mission begins.

I sat in a room full of some of the smartest physiologists, engineers, and physicians on the planet — people who have built an incredible mechanistic understanding of each individual piece of the human system — and I noticed something. They are extraordinarily good at taking the machine apart. They are still working on how to put it back together and look at it as a whole.

This is not a criticism. It is how science works. You have to understand the parts before you can model the system. But it is also the gap where I believe the real answer lives — in the integration of sleep, HRV, nutrition, strength, cognitive load, and longitudinal baseline data into a picture that tells you not just where someone is today, but where they are headed, and whether they are going into their next mission with a full bucket or an empty one.

The takeaway for you is simpler than the science behind it: resilience is built before it is needed. The 30-day recovery only works if the pre-mission work was done. Go find your edge before the environment finds it for you.

There is a timing reality in that room that almost nobody outside of it understands yet.

NASA's human performance research has historically operated on 25-year timelines. You develop a hypothesis, design a study, fly a crew, collect data, publish, iterate. The science is extraordinarily rigorous and the results are real — but the pace was built for an era when the mission calendar had margin.

That era is over. The Artemis timeline is compressing. Lunar surface missions with high-tempo EVA schedules are being planned for 2027 and 2028. Mars is no longer an abstract destination — it is an active engineering problem. And the gaps between what NASA knows and what it needs to know before those missions fly are significant, documented, and open.

Here is the part that matters for anyone paying attention: they are actively asking industry to come in and fill them. Not quietly. Explicitly. The message from the floor was direct — bring solid preliminary research, show why your technology addresses a documented gap, and there is a pathway to get your solution into a real mission environment. The door is open. The requirements are published. Most people just haven't shown up yet.

I had a conversation after one of the sessions with the researcher leading NASA's cognitive performance program. She described exactly the kind of dashboard her team needs — a real-time integration of sleep quality, HRV, CGM data, and macros tracked over three days or more that correlates reliably to cognitive performance outcomes. Her team knows what they want to build. They do not yet have the framework for how to build it. That is not a research gap. That is a product gap sitting inside one of the most credentialed institutions on earth, surrounded by a funding and mission imperative to solve it.

And then there was the conversation I had over lunch with a researcher from West Virginia University doing parabolic flight data analysis — studying how the vascular, motor, and sensory systems respond to zero gravity transitions. Her goal is to translate those findings into stroke rehabilitation protocols. Space research, applied directly to one of the most common and devastating neurological events in clinical medicine. The investment thesis is not complicated: the science is real, the need is massive, and the proof-of-concept work is already being done by underfunded researchers who have no platform to amplify it.

I talked with Kim — the person whose job it is to get this information out of NASA and into the hands of people who can act on it. She told me directly that getting industry to pay attention to the gaps and the opportunities is genuinely difficult. The research is not being communicated in a language that investors and builders recognize as investable. This newsletter is my attempt to start translating.

The public version of astronaut physiology is a simplified story: muscle wastes, bones thin, they come back and recover. What was presented in that room over two days was considerably more complex, more interesting, and in several cases, more alarming than the public version suggests.

Start with exercise physiology. NASA's current ISS protocol has crews training approximately two and a half hours per day — roughly 25 minutes of aerobic work at 70-90% of max heart rate, plus 40 minutes to an hour of resistive training six days per week. Against this backdrop, the mean VO2 max loss on orbit is approximately 7%, well below the 20% threshold that NASA established decades ago as the acceptable ceiling. Muscle strength decline follows a similar pattern, with most crew returning within the defined parameters. On paper, this looks like a solved problem.

It is not a solved problem. The headline number hides the variance that makes it scientifically intractable. Some crew members return from six-month missions with VO2 max values that have barely moved. Others lose significantly more than the mean, and the predictive tools to identify which person will fall into which group do not currently exist. After twenty-five years of continuous human presence on the ISS, NASA cannot reliably correlate the exercise performed in microgravity with the physiological outcome post-landing. The upstream variable — whatever separates the highly resilient from the vulnerable — remains unidentified.

Bone is more complicated than the commonly cited "1% loss per month" figure implies. What's actually happening is a remodeling process — trabecular bone (the internal lattice structure that provides compressive strength) is being resorbed faster than it's being rebuilt, while cortical bone (the dense outer shell) follows a different pattern at different skeletal sites. The structural integrity question — whether remodeled bone is as load-resistant as pre-flight bone — is genuinely unsettled. Finite element modeling of astronaut bone is ongoing, but the data needed to answer the Mars-duration question doesn't exist yet.

The hidden risks are where this gets operationally serious. Spaceflight Associated Neuro-ocular Syndrome — SANS — was not identified until 2018-2019 despite decades of continuous spaceflight. It involves intracranial fluid shifts that cause structural changes to the eye: optic disc edema in approximately two-thirds of crew members, choroidal retinal folds that can progress into the central visual field if the mission is long enough, and vision changes requiring prescription adjustment in about 20% of flyers. There is currently no treatment except returning to Earth. For a Mars mission, that option doesn't exist.

Separately, venous thrombosis — specifically internal jugular vein clots — began appearing in the data in the early 2020s. These are extraordinarily rare in terrestrial populations, which makes their appearance in otherwise healthy, fit astronauts significant. The leading hypothesis involves chronic cephalad fluid shift reducing venous return velocity in the left internal jugular vein. Studies are now underway, but the predictive model for who is at risk, and when prophylactic anticoagulation should be initiated, doesn't exist yet. The tradeoff — blood thinners in a population that may need to perform high-risk EVA operations — is not trivial.

The immune system deserves its own paragraph because the mechanism is both elegant and sobering. Spaceflight drives cortisol elevation, which suppresses T cell cytotoxic function while simultaneously activating innate immune pathways in a compensatory pattern. The result is a dysregulated system that can't mount a proper adaptive response. The clinical marker that NASA uses to track this in real time is latent herpes virus reactivation — specifically Epstein-Barr Virus in saliva samples. In the early ISS era, with inadequate exercise hardware and protocols, nearly every crew member showed evidence of viral reactivation. In the modern era, with high-intensity resistance and aerobic protocols, this has been largely suppressed. The mechanism: exercise induces acute sympathetic nervous system activation, which releases epinephrine, which directly binds to immune cells and mobilizes combat-ready leukocytes into circulation. Contracting muscle releases myokines that rebalance cytokine ratios. Resistance exercise specifically reverses the danger-associated molecular patterns (DAMPs) released during tissue breakdown in microgravity. The key finding: crew members with higher pre-flight VO2 max who also maintained conditioning on orbit had dramatically lower rates of viral reactivation than those who started lower and declined further.

Fitness is immune medicine. The mechanism is now documented.

Artemis EVAs are not ISS EVAs. The operational picture is categorically different, and the human performance requirements that follow from it are still being worked out in real time.

ISS crews perform two to three EVAs per six-month mission. Artemis surface mission planning calls for up to four EVAs in five days — what the community is calling "high-tempo EVA cadence" — with individual EVAs averaging six hours and extending to eight. The Artemis spacesuit (being developed by Axiom Space under the xEMU commercial contract) has a mass requirement that is more than double the Apollo suit. The suit is self-supporting in the sense that it bears its own weight, but the inertia, the joint resistance, and the metabolic cost of moving within it fall entirely on the crew member. Couple that with a lunar South Pole environment featuring extreme lighting contrast — either blinding direct sun or shadows so deep that terrain features become unreadable — and you have a performance environment that has no historical analog.

NASA's exercise physiology lab synthesized Apollo metabolic data, literature on high-intensity occupational demands, and Neutral Buoyancy Lab simulations to estimate sustainable workload on the lunar surface. The convergent answer across all three sources: 30-50% of maximum aerobic capacity is the sustainable operational range. At the low end, highly fit crew members working in relative comfort. At the high end, crew members who are less fit, or performing peak-demand tasks like crew rescue or steep terrain traverse, running close to their ceiling for extended periods.

The fitness threshold data from a recent pilot study adds specificity. Comparing crew members who met versus didn't meet NASA's current deadlift standard against simulated EVA task performance: those who met the strength standard could carry a payload bag an additional 50 meters, perform incapacitated crew rescue for an additional 30 minutes, and traverse an additional 60 meters in the allotted period. Those who met the bench press minimum standard dragged a simulated crew member 20 more meters. These aren't marginal differences. In a mission where the traverse from the lander to a science site and back is a fixed distance, fitness isn't an abstract health metric — it's a binary question of whether the task gets completed.

The cognitive load dimension of EVA performance is almost entirely absent from public discussion of astronaut fitness, and it is among the more sophisticated research programs at JSC right now. A crew member on a lunar surface traverse is simultaneously navigating unfamiliar terrain with compressed shadows that misrepresent slopes and distances, monitoring suit consumables in real-time, coordinating with a second EVA crew member and two crew members inside the lander, managing communication with Mission Control on a delay, tracking geological samples, and executing a predetermined timeline that accounts for no slack. Each of these demands draws from a shared cognitive capacity pool. The NASA behavioral health lab has demonstrated that high-difficulty geological sampling tasks measurably reduce working memory performance on subsequent tests — meaning the hard science task done early in an EVA degrades the cognitive resources available for everything that follows.

The sensory-motor picture compounds this further. Post-landing neuro-vestibular disruption in Artemis missions is expected to be worse than Apollo because of mission architecture: where Apollo flew a roughly 4.5-day transit to the Moon, Artemis trajectories involving orbital rendezvous extend transit time to 10-12 days — long enough that motion sickness incidence climbs significantly, and sensory-motor adaptation to microgravity is further consolidated. These crew members will be landing on the lunar surface, suiting up, and beginning EVA operations while their vestibular system is still recalibrating. The go/no-go decision tools for EVA readiness in that specific window don't exist yet.

The last session of the summit was the most surprising two hours of the conference. A panel of researchers presented three countermeasure concepts that have no precedent in the standard human spaceflight toolkit. None of them are ready to fly. All of them are real.

This is not science fiction. Dr. Kate Flickinger's lab at the University of Pittsburgh has run a proof-of-concept protocol in human subjects. The mechanism draws on the biology of hibernating animals — specifically the fact that hibernation achieves metabolic reduction primarily through the manipulation of the temperature-metabolism relationship. Bears hibernate at shallow temperature and metabolic reduction. Wood frogs push this to the extreme of near-freezing, surviving metabolic states that would kill a human. The question Flickinger's lab asked: can we induce intermediate hibernation-like traits in humans safely enough to be relevant?

The protocol used dexmedetomidine — a fast-on, fast-off sedative that critically does not suppress the respiratory drive — delivered via subcutaneous infusion pump. Core temperature was reduced slightly. Sleep-wake ratio was inverted to 20 hours sleep, 4 hours awake. During that four-hour window, subjects performed cognitive batteries, exercised, and ate. The metabolic savings come from three compounding effects: sleep naturally reduces metabolic rate below rest; the sedative reduces it further; and the mild hypothermia reduces it again. The result is a state of controlled shallow metabolic reduction maintained across five consecutive days.

The critical findings: subjects maintained their VO2 peak and heart rate peak during the exercise windows — meaning they could still perform physically during the wake period. Cognitive function was preserved. Mood did not significantly degrade across the five-day protocol. Musculoskeletal health changes are still being analyzed. Six subjects is a proof of concept, not a clinical trial. The implications if it scales are profound: slower deconditioning, reduced oxygen consumption reducing ECLSS load on the spacecraft, reduced psychological burden of transit time, and — in hibernating animals — increased radiation tolerance during metabolic suppression. Whether that radiation protection transfers to humans is unknown and being asked.

The second frontier concept comes from regenerative biology. The piezo proteins — specifically Piezo1 — are mechanosensitive ion channels embedded in cell membranes throughout the body. Under normal gravitational loading, physical forces deform the cell membrane, opening the piezo channel and allowing cation influx that triggers downstream signaling cascades specific to the cell type. In osteoblasts, piezo activation drives bone formation. In microgravity, reduced mechanical load means the channel stays closed, osteoblast activity drops, and osteoclast activity increases unopposed — the normal bone loss pattern.

What the Dolan lab at Arizona State has begun exploring is pharmacological piezo activation: synthetic agonists called Yoda1 (and its successor Yoda2) that act as "door chips" — binding within the Piezo1 channel and holding it in a partially open state, effectively simulating mechanical load without any physical force being applied. In unloaded animal models, Yoda1 treatment preserves bone mass and skeletal muscle integrity, increases osteoblast formation, and maintains skeletal function. There is currently no clinical pharmacokinetic data. The concept is early. But for a Mars mission where exercise hardware may be resource-constrained and gravitational loading is absent for months of transit, a pharmacological analog of mechanical loading is a genuinely novel approach to a problem that exercise alone cannot fully solve.

The third concept is whole-body low-intensity vibration — a technology that has been in and out of research conversation for decades but is gaining renewed mechanistic credibility. The mechanism connects directly to piezo biology: sub-gravitational vibration at 20-200Hz delivers high-frequency, low-magnitude mechanical signals to bone and muscle that activate Piezo1 through membrane deformation, driving downstream osteoblast activity without the oxygen cost or equipment demands of traditional resistance exercise. Pagnotti's lab at UT MD Anderson demonstrated preservation of trabecular bone volume in models of age and hormone-related bone loss over 30-week protocols. When paired with bisphosphonate therapy — an anti-resorptive agent that prevents osteoclast activity — the combination outperformed either intervention alone. The combinatorial insight is the key finding: no single countermeasure closes the performance gap. The future is stacked protocols.

The people in that room are solving for Mars. But every mechanism they're uncovering — the variability in resilience, the immune dysregulation, the bone that remodels under stress, the cognitive load that degrades performance before anyone notices — these are not astronaut problems. They are human problems. They are your problems. The extreme environment just makes the biology visible faster.

Next week: the full industry gap map. Six documented problems with no current solution, a timeline that is compressing, and a door that is open to anyone willing to show up with the right research. That's the Deloitte-style report. This was the field dispatch that earns it.

Go find your edge. That's where resilience lives.

— Dr. Dave

Guild of the Wild — The frontier of human possibility. Field tested. Truth told.

If this Field Note made you think differently about something — forward it to one person who needs to hear it. The right ideas find the right people when we pass them along.

And if something in here sparked a question, a story, or a thought you can't shake — hit reply. I read every one.